Complementary and Alternative Medicine for Urological Symptoms (CAMUS)
泌尿系统症状的补充和替代医学 (CAMUS)
基本信息
- 批准号:7988841
- 负责人:
- 金额:$ 12.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-30 至 2011-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAge-YearsAmericanBenefits and RisksBenign Prostatic HypertrophyBlood Chemical AnalysisCaliforniaChronic ProstatitisClinicalClinical TrialsCommitCommittee MembersComplementary and alternative medicineComplete Blood CountConflict (Psychology)DataData CollectionData SetDoseDouble-Blind MethodEnrollmentEuropeFunctional disorderFundingIncontinenceInterventionMeasurementMeasuresNocturiaPaperParticipantPatient observationPharmaceutical PreparationsPhytotherapyPlacebo ControlPlacebosPrincipal InvestigatorProceduresProcessProstate-Specific AntigenProtocols documentationPublicationsQuality of lifeRandomized Clinical TrialsResidual volumeSabal serrulataSaw Palmetto Berry ExtractSaw palmetto extractSiteSleepSpecific qualifier valueSymptomsTechniquesTimeUncertaintyUnited States National Institutes of HealthUrineVisitWorkarmbaseclinical research sitedietary supplementseligible participantexperiencefollow-upindexinglower urinary tract symptomsmenolder menpillprimary outcomepublic health relevancetrial comparingurologic
项目摘要
DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is a common problem for older men. Several treatment options exist for BPH, including watchful waiting, prescription medications, and invasive procedures. Despite the availability of these conventional approaches, millions of men in the U.S. have chosen to use complementary and alternative medicine (CAM) to treat their symptoms. Most common among CAM approaches is the use of non-prescription extracts of the saw palmetto berry. Saw palmetto has been used for centuries by native cultures to address lower urinary tract symptoms (LUTS) and this herbal therapy is used commonly in Europe, often as first-line therapy. Several prior studies suggested that saw palmetto may have specific efficacy in reducing bothersome LUTS, but more recent data have raised some doubts about this assertion.
The CAMUS study is a two-arm, double-blind, placebo-controlled randomized clinical trial comparing three escalating doses of a saw palmetto extract to an identical-appearing placebo. Beginning in mid-2008, 369 participants have been enrolled at 11 participating clinical centers and are being followed for 18 months for a primary outcome of change in the American Urological Association Symptom Index (AUASI) scores. Eligible participants are men at least 45 years of age who have an AUASI score between 8 and 24, a peak urine flow of at least 4 ml/sec, a prostate-specific antigen <10 ng/dl, and no prior invasive BPH intervention.
This proposal is for the continuation of the Kaiser Permanente, Northern California (KPNC) CAMUS site. Forty participants are enrolled at KPNC and all remain in the study. Adherence has been excellent: we have experienced no missed study visits and pill adherence has ranged from 79-90%. The site PI, Dr. Andrew Avins, is an active Steering Committee member and chairs the Protocol Adherence Committee.
Plans for the final year of the KPNC clinical site consist of continuing to follow all participants and working to maintain their outstanding adherence to date. We will employ all feasible techniques to encourage participant adherence and maintain high-quality data collection. All participants will be closed out during this fund year, a process that will require substantial effort in repeating all baseline measurements, arranging for final follow-up, and verifying all study data and regulatory compliance issues. The KPNC site is committed to continuing to provide outstanding data for the final year of the CAMUS study and continuing its active participation in this pivotal clinical trial.
PUBLIC HEALTH RELEVANCE: Millions of men in the U.S. take saw palmetto extracts for their symptoms of BPH. Whether saw palmetto is safe and effective for these men is unclear as existing data are conflicting. The Kaiser Permanente, Northern California site of the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) clinical trial is helping to better define the risks and benefits of saw palmetto by contributing to the most definitive data to date on the clinical value of this widely used dietary supplement.
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew L Avins其他文献
Andrew L Avins的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew L Avins', 18)}}的其他基金
The Kaiser Permanente National Research Database
凯撒医疗机构国家研究数据库
- 批准号:
7940818 - 财政年份:2009
- 资助金额:
$ 12.59万 - 项目类别:
The Enigma of Placebo Adherence and Health Outcomes
安慰剂依从性和健康结果之谜
- 批准号:
7641046 - 财政年份:2006
- 资助金额:
$ 12.59万 - 项目类别:
The Enigma of Placebo Adherence and Health Outcomes
安慰剂依从性和健康结果之谜
- 批准号:
7457992 - 财政年份:2006
- 资助金额:
$ 12.59万 - 项目类别:
The Enigma of Placebo Adherence and Health Outcomes
安慰剂依从性和健康结果之谜
- 批准号:
7275424 - 财政年份:2006
- 资助金额:
$ 12.59万 - 项目类别:
The Enigma of Placebo Adherence and Health Outcomes
安慰剂依从性和健康结果之谜
- 批准号:
7101149 - 财政年份:2006
- 资助金额:
$ 12.59万 - 项目类别:
相似国自然基金
基于保护动机理论的新确诊青少年HIV感染者抗病毒治疗依从性“游戏+”健康教育及作用机制研究
- 批准号:82304256
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于前景理论的ADHD用药决策过程与用药依从性内在机制研究
- 批准号:72304279
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于HAPA理论的PCI术后患者运动依从性驱动机制与干预方案构建研究
- 批准号:72304180
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于强化学习AI聊天机器人对MSM开展PrEP服药依从性精准干预模式探索及干预效果研究
- 批准号:82373638
- 批准年份:2023
- 资助金额:59 万元
- 项目类别:面上项目
CAS理论视角下农村老年心血管代谢性共病管理依从性的社区-患者协同机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Enhanced Medication Management to Control ADRD Risk Factors Among African Americans and Latinos
加强药物管理以控制非裔美国人和拉丁裔的 ADRD 风险因素
- 批准号:
10610975 - 财政年份:2023
- 资助金额:
$ 12.59万 - 项目类别:
Improving sleep and circadian functioning, daytime functioning, and well-being for midlife and older adults by improving patient memory for a transdiagnostic sleep and circadian treatment
通过改善患者对跨诊断睡眠和昼夜节律治疗的记忆,改善中年和老年人的睡眠和昼夜节律功能、日间功能和福祉
- 批准号:
10708424 - 财政年份:2023
- 资助金额:
$ 12.59万 - 项目类别:
Yuva Sath: A peer-led intervention to support substance use treatment and HIV prevention among young people who inject drugs in India
Yuva Sath:一项由同伴主导的干预措施,旨在支持印度注射吸毒年轻人的药物滥用治疗和艾滋病毒预防
- 批准号:
10698376 - 财政年份:2023
- 资助金额:
$ 12.59万 - 项目类别:
Exploring, Predicting, and Intervening on Long-term Viral suppression Electronically (EPI-LoVE)
电子方式探索、预测和干预长期病毒抑制 (EPI-LoVE)
- 批准号:
10676683 - 财政年份:2023
- 资助金额:
$ 12.59万 - 项目类别:
Integrated delivery of cancer control interventions for adolescents and young adults living with HIV in Zambia
为赞比亚艾滋病毒感染者提供综合癌症控制干预措施
- 批准号:
10878015 - 财政年份:2023
- 资助金额:
$ 12.59万 - 项目类别: